Benzylpiperazine a 'new drug of abuse'

NewsGuard 100/100 Score

Professor Alison Jones said benzylpiperazine was a 'new drug of abuse' which could have serious clinical effects - similar to those of ecstasy to which it is structurally related.

The finding appears in a paper co-authored by Professor Jones in this week's edition of the prestigious international medical journal , The Lancet.

In the paper Professor Jones from the University of Newcastle and her toxicology colleagues, from Guy's and St Thomas, Hospital in London and St Georges, Hospital London Drug Testing Laboratory, show for the first time the presence of a new drug of abuse , benzylpiperazine.

Professor Jones said while benzylpiperazine was prohibited in Australia, the drug was readily available in the United Kingdom.

"This drug is currently unrestricted in the UK. Its availability and detection in patients in the UK who have come to harm, raises significant issues of clinical problems and access," said Professor Jones. Now in Australia, Professor Jones has joined the University of Newcastle and the Hunter Medical Research Institute as Professor of Medicine and Clinical Toxicology. She is also a clinician at the Newcastle Mater Hospital and responsible for providing education and toxicology advice to clinicians.

Professor Jones comes to Newcastle from Guy's and St Thomas' Hospital in London, where she was formerly the Director of the National Poisons Information Service. She brings with her a wealth of experience in clinical medicine, teaching and research.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis